YARW — YARROW BIOSCIENCE Share News
0.000.00%
Last trade - 00:00- $181.86m
- $158.94m
- $0.57m
Brief: Vyne Therapeutics Provides Program Update On Oral BET Inhibitor VYN202
Vyne Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary
Vyne Therapeutics Inc expected to post a loss of 29 cents a share - Earnings Preview
Vyne Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: VYNE Therapeutics FY Revenue USD 501 Thousand
Vyne Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
Brief: Vyne Therapeutics Initiates Phase 1B Trial Of Vyn202, A Novel Bd2-Selective Oral Bet Inhibitor, In Plaque Psoriasis
Brief: Vyne Therapeutics Cash Runway Extends Into Second Half Of 2026
Brief: Vyne Therapeutics Completes Enrollment In Phase 2B Trial Evaluating VYN201
Vyne Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview
Brief: VYNE Therapeutics Q3 Basic EPS USD -0.29
Vyne Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: VYNE Therapeutics Q2 Basic EPS USD -0.22
Vyne Therapeutics Inc expected to post a loss of 19 cents a share - Earnings Preview
Brief: VYNE Therapeutics Announces Granting of Composition of Matter Patent for VYN202
Brief: VYNE Therapeutics Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development
Brief: Vyne Therapeutics Announces Dosing Of First Participants In Phase 1a Trial Of Novel BD2-Selective Bet Inhibitor VYN202
Brief: VYNE Therapeutics Announces Dosing of First Subject in Phase 2b Vitiligo Trial of Novel BET Inhibitor VYN201
Vyne Therapeutics Inc reports results for the quarter ended in January - Earnings Summary